These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26785228)

  • 61. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multi-drug resistant Pseudomonas aeruginosa keratitis and its effective treatment with topical colistimethate.
    Chatterjee S; Agrawal D
    Indian J Ophthalmol; 2016 Feb; 64(2):153-7. PubMed ID: 27050354
    [TBL] [Abstract][Full Text] [Related]  

  • 63. ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study.
    Hua X; Li C; Pogue JM; Sharma VS; Karaiskos I; Kaye KS; Tsuji BT; Bergen PJ; Zhu Y; Song J; Li J
    JMIR Mhealth Uhealth; 2020 Dec; 8(12):e20525. PubMed ID: 33325835
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.
    Li J; Rayner CR; Nation RL; Deans R; Boots R; Widdecombe N; Douglas A; Lipman J
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4814-5. PubMed ID: 16251342
    [No Abstract]   [Full Text] [Related]  

  • 65. Colistin: how should it be dosed for the critically ill?
    Landersdorfer CB; Nation RL
    Semin Respir Crit Care Med; 2015 Feb; 36(1):126-35. PubMed ID: 25643276
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion.
    Viel A; Henri J; Bouchène S; Laroche J; Rolland JG; Manceau J; Laurentie M; Couet W; Grégoire N
    Pharm Res; 2018 Mar; 35(5):92. PubMed ID: 29532176
    [TBL] [Abstract][Full Text] [Related]  

  • 67. On the path to untreatable infections: colistin use in agriculture and the end of 'last resort' antibiotics.
    Watkins RR; Smith TC; Bonomo RA
    Expert Rev Anti Infect Ther; 2016 Sep; 14(9):785-8. PubMed ID: 27454763
    [No Abstract]   [Full Text] [Related]  

  • 68. Antibiotic dosing in slow extended daily dialysis.
    Mushatt DM; Mihm LB; Dreisbach AW; Simon EE
    Clin Infect Dis; 2009 Aug; 49(3):433-7. PubMed ID: 19580416
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched Series.
    Trifi A; Abdellatif S; Daly F; Mahjoub K; Nasri R; Oueslati M; Mannai R; Bouzidi M; Ben Lakhal S
    Chemotherapy; 2016; 61(4):190-6. PubMed ID: 26863534
    [TBL] [Abstract][Full Text] [Related]  

  • 70. NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
    Nolan K; Knight H; Clark P
    Lancet Respir Med; 2013 Apr; 1(2):102-3. PubMed ID: 24429083
    [No Abstract]   [Full Text] [Related]  

  • 71. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
    Li J; Nation RL; Turnidge JD; Milne RW; Coulthard K; Rayner CR; Paterson DL
    Lancet Infect Dis; 2006 Sep; 6(9):589-601. PubMed ID: 16931410
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dose adjustment of polymyxins for renal insufficiency.
    Zavascki AP
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4940. PubMed ID: 21921118
    [No Abstract]   [Full Text] [Related]  

  • 73. Returning to the pre-antibiotic era in the critically ill: the XDR problem.
    Paterson DL; Lipman J
    Crit Care Med; 2007 Jul; 35(7):1789-91. PubMed ID: 17581370
    [No Abstract]   [Full Text] [Related]  

  • 74. Novel multidrug resistant microorganisms in critically ill: a potential threat.
    Grossi PA; Tebini A; Dalla Gasperina D
    Minerva Anestesiol; 2015 Jan; 81(1):52-64. PubMed ID: 24594917
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comment on: pharmacokinetics of inhaled colistin in patients with cystic fibrosis.
    Li J; Nation RL
    J Antimicrob Chemother; 2006 Jul; 58(1):222-3; author reply 223. PubMed ID: 16641116
    [No Abstract]   [Full Text] [Related]  

  • 76. Systematic review of the evidence for rational dosing of colistin.
    Kift EV; Maartens G; Bamford C
    S Afr Med J; 2014 Mar; 104(3):183-6. PubMed ID: 24897820
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
    Tang HJ; Chuang YC; Ko WC; Chen CC; Shieh JM; Chen CH; Lee NY; Chiang SR
    Int J Infect Dis; 2012 Jan; 16(1):e34-40. PubMed ID: 22088863
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Nosocomial pneumonia caused by multiresistant Acinetobacter baumanii treated by colistin and rifampicin].
    Motaouakkil S; Charra B; Hachimi A; Benslama A
    Ann Fr Anesth Reanim; 2006 May; 25(5):543-4. PubMed ID: 16488103
    [No Abstract]   [Full Text] [Related]  

  • 79. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses.
    Marchand S; Lamarche I; Gobin P; Couet W
    J Antimicrob Chemother; 2010 Aug; 65(8):1753-8. PubMed ID: 20507861
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Intrathecal use of colistin].
    Charra B; Hachimi A; Benslama A; Motaouakkil S
    Ann Fr Anesth Reanim; 2006 Feb; 25(2):215. PubMed ID: 16311006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.